argenx SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy Van Hauwermeiren
- Full Time Employees
- 1,863
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101EB
- IPO Date
- May 18, 2017
- CIK
- 0001697862
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE, a commercial-stage global immunology company, develops and commercializes differentiated antibody-based therapies targeting severe autoimmune diseases using its proprietary Immunology Innovation Program and SIMPLE Antibody platform; its lead product VYVGART (efgartigimod) is an FcRn blocker approved for generalized myasthenia gravis in the United States, Europe, Japan, Israel, Canada and Mainland China, as well as for chronic inflammatory demyelinating polyneuropathy, with subcutaneous formulations including pre-filled syringes launched to enhance patient access and ongoing label expansions into broader myasthenia gravis populations such as seronegative, pediatric and ocular via studies like ADAPT-SERON, ADAPT-JR and ADAPT-OCULUS; the pipeline features advancing candidates like ARGX-213 targeting FcRn, ARGX-121 for IgA, ARGX-109 for IL-6 and ARGX-220 as a novel sweeping antibody, alongside earlier programs and out-licensed assets including LP0145 (ARGX-112) to LEO Pharma for atopic dermatitis, AGMB-101 (ARGX-114) to AgomAb Therapeutics for fibrotic diseases and ARGX-115 (ABBV-151) to AbbVie for oncology. argenx SE operates in key markets including the United States, Europe, Japan and Greater China through partnerships such as with Zai Lab; it was founded in 2008 in Ghent, Belgium by Tim van Hauwermeiren, Hans de Haard and Torsten Dreier, with headquarters in Amsterdam, Netherlands, and maintains subsidiaries like argenx BV in the Netherlands, argenx SAS in France and argenx UK Ltd. Recent developments include expansion of VYVGART into immune thrombocytopenia and multifocal motor neuropathy via registrational programs like ADVANCE and EMPASSION with topline data anticipated, autoinjector development for 2027 launch, four new pipeline nominations through the Immunology Innovation Program in 2025, sustained R&D investment supported by approximately EUR 2.6 billion in cash equivalents as of late 2024, and global commercial infrastructure growth alongside strategic collaborations leveraging technologies like Halozyme's subcutaneous delivery.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
argenx to Host Myositis R&D Webinar on June 23, 2026
argenx to Present at Upcoming Investor Conferences
argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System
The Biology Came First.
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease